zealand pharma petrelintide - Search News

Zealand Pharma to pay $350M to Roche

The Wall Street Journal on MSN · 2d

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Medical Dialogues · 19h

Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate

Markets Insider · 2d

Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a

2d

Roche And Zealand Team Up To Develop Petrelintide

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

2don MSN

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Fierce Biotech2d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

2don MSN

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results